secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-09-08T12:00:30+00:00
Accession:  0001213900-26-097851
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics CMO – Urology Raj Pruthi departs effective Sept 3, 2026
----------------------------------------------------------------------------

- Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026.
- No replacement or successor for the CMO – Urology role was named in the filing.
- Departure was reported under Item 8.01; no reason or transition details provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/0001213900-26-097851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-097851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer